Empagliflozin is a drug of the gliflozin class, approved for the treatment of type 2 diabetes in adults in 2014. Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuronic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, therefore resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycemia and also assists in weight loss and blood pressure reduction.
Mechanism of Action of Empagliflozin
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuronic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycemia, assists weight loss, and reduces blood pressure.
Indications of Empagliflozin
- Type 2 Diabetes Mellitus
- Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
- Empagliflozin is primarily used in type 2 diabetics to lower blood glucose levels. Empagliflozin in people with type 2 diabetes reduces the risk of heart attacks and heart failure
- An adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.
- To reduce the risk of cardiovascular (CV) death in adult patients with type 2 diabetes mellitus and established CV disease.
- indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- As monotherapy when metformin is considered inappropriate due to intolerance
- In addition to other medicinal products for the treatment of diabetes
- For study results with respect to combinations, effects on glycaemic control and cardiovascular events,
Contra-Indications of Empagliflozin
- Infection
- Low blood sugar
- Pituitary hormone deficiency
- Decreased function of the adrenal gland
- Inadequate vitamin B12
- Excess body acid
- Extreme loss of body water
- The habit of drinking too much alcohol
- Alcohol intoxication
- Heart attack
- Suddenly serious symptoms of heart failure
- Liver problems
- Recent operation
- Fever
- Shock
- Severe vomiting
- Severe diarrhea
- Serious lack of oxygen in the blood
- Weakened patient
- Injury
- Sepsis syndrome
- X-Ray Study with intravenous iodine contrast agent
- Kidney disease with a likely reduction in kidney function
- Acute inflammation of the pancreas
- Chronic inflammation of the pancreas
- Moderate to Severe kidney impairment.
Dosage of Empagliflozin
Strengths: 10 mg; 25 mg
Diabetes Type 2
- Initial dose: 10 mg orally once a day in the morning
- May increase to 25 mg orally once a day for patients tolerating therapy
- Maximum dose: 25 mg per day
Cardiovascular Risk Reduction
- Initial dose: 10 mg orally once a day in the morning
- May increase to 25 mg orally once a day for patients tolerating therapy
- Maximum dose: 25 mg per day
Side Effects of Empagliflozin
Most common
- Abdominal or stomach discomfort
- increased urination.
- low blood pressure,
- difficult, burning, or painful urination
- discharge with a strong odor from the penis
- increased potassium blood levels (hyperkalemia),
- low blood sugar (hypoglycemia), and
- diarrhea
- gas (flatulence)
- symptoms of weakness, muscle pain (myalgia)
- upper respiratory tract infection
- low blood sugar (hypoglycemia)
- abdominal pain (GI complaints), lactic acidosis (rare)
- low blood levels of vitamin B-12
- nausea, vomiting
- chest discomfort
- chills, dizziness
- bloating/abdominal distention
- constipation
- heartburn
More common
- Abdominal or stomach discomfort
- cough or hoarseness
- decreased appetite
- diarrhea
- fast or shallow breathing
- fever or chills
- general feeling of discomfort
- lower back or side pain
- muscle pain or cramping
- painful or difficult urination
Less common
- Abnormal stools
- bad, unusual, or unpleasant (after) taste
- change in taste
- difficulty with moving
- discoloration of the fingernails or toenails
- flu-like symptoms
- joint pain
- rash
- a runny nose
- sneezing
- stuffy nose
- swollen joints
Drug Interactions of Empagliflozin
Canagliflozin may interact with following drugs, supplements & may decrease the efficacy of the drug
- androgens (e.g., methyltestosterone, nandrolone, testosterone)
- angiotensin-converting enzyme inhibitors (ACEIs; captopril, ramipril)
- angiotensin receptor blockers (ARBs; e.g., candesartan, irbesartan, losartan)
- angiotensin-converting enzyme inhibitors (ACEIs; captopril, enarapril, ramipril)
- antipsychotic medications (e.g., chlorpromazine, haloperidol, olanzapine,
- birth control pills
- bupropion
- atorvastatin
- atypical antipsychotics (e.g., aripiprazole, clozapine, olanzapine; quetiapine, risperidone)
- “azole” antifungals (e.g., itraconazole, ketoconazole, voriconazole)
- barbiturates (e.g., pentobarbital, phenobarbital)
- crizotinib
- cyclosporine
- lanreotide
- levodopa
- mifepristone
- corticosteroids (e.g., dexamethasone, prednisone)
- diabetic drugs (e.g., glyburide, insulin, repaglinide, sitagliptin)
- digoxin
- diuretics (e.g., furosemide, hydrochlorothiazide)
- HIV protease inhibitors (e.g., atazanavir, indinavir, ritonavir, saquinavir)
- iodinated contrast material
- phenytoin
- quinolone antibiotics (e.g., levofloxacin, moxifloxacin)
- selective serotonin reuptake inhibitors (SSRIs; citalopram, fluoxetine, sertraline paroxetine,
- trimethoprim
- teriflunomide
- vorinostat
- verapamil
Pregnancy & Lactation of Empagliflozin
FDA Pregnancy Category C
Pregnancy
This medication should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking this medication, contact your doctor immediately.
Lactation
It is not known if empagliflozin passes into breast milk. If you breastfeeding-feeding mother and are taking this medication, it may affect your baby. Talk to your doctor about whether you should continue breastfeeding.
References

About the author